Cryo Cell International price to free cash flow CCEL

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026: 7.7×
10-year median: 9.3×
Against its 10-year history: 23rd; percentile: 0 is its lowest day, 100 its highest
10-year range: 4.3× to 29.7×
Peer median: 11.8×

Cryo Cell International's price to free cash flow is 7.7× as of Oct 23, 2026.

That is below its ten-year median of 9.3×, lower than on 77% of days in the last ten years.

Over that time it ranged from 4.3× in Jan 2026 to 29.7× in Mar 2024.

The median for 10 healthcare stocks of a similar size is 11.8×.

Price to free cash flow over time

median 9.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.7×	4.3×	7.7×
2025	4.6×	4.6×	22.5×
2024	20.2×	13.9×	29.7×
2023	16.4×	12.3×	18.1×
2022	9.8×	9.6×	14.3×
2021	13.0×	7.9×	15.0×
2020	9.0×	7.3×	10.7×
2019	10.4×	8.7×	13.0×
2018	9.5×	7.6×	14.9×
2017	11.3×	6.9×	11.3×
2016	7.6×	5.8×	10.0×
2015	9.6×	9.4×	22.7×
2014	26.0×	21.1×	50.9×
2013	21.4×	12.9×	106×
2012	71.3×	71.3×	89.7×

Against its peers

Companies in Healthcare nearest Cryo Cell International's size, closest first, today.

Company	Price to free cash flow
CCELCryo Cell International	7.7×
NEPHNephros	n/m
ATNMActinium Pharmaceuticals	n/m
APTAlpha Pro Tech	9.7×
SPROSpero Therapeutics	n/m
LFVNLifevantage	11.0×
ICCCImmucell	22.1×
KEQUKewaunee Scientific	8.7×
PDEXPro DEX	29.5×
PLXProtalix BioTherapeutics	26.8×
NATRNatures Sunshine Products	11.8×
Peer median	11.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Cryo Cell International

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.